Company intelligence / Profile preview

Arch Biopartners

Toronto, Ontario, Canadaarchbiopartners.com ↗

Ownership: Public · ARCH
Development stage: Other

Overview

Arch Biopartners has advanced its lead candidate LSALT peptide into international Phase II trials for the prevention of cardiac surgery-associated acute kidney injury. The company has demonstrated safety up to a daily dose of 20 mg in healthy volunteers. Recruitment for the CS-AKI trial is ongoing at multiple sites globally, with positive progress reported. Preclinical data support efficacy via DPEP1 pathway inhibition to prevent organ damage from inflammation. Additional programs include cilastatin for toxin-induced AKI and AB569 for antibiotic-resistant infections.

Therapeutic areas: ImmunologyInfectious DiseasesPulmonologyNephrology
Modalities: Peptides (e.g., LSALT peptide/Metablok)Small molecules (e.g., cilastatin)Antibodies
Industry: Biotech

Partnerships

Collaborations with University of CalgaryUniversity Health Network/Toronto General HospitalUniversity of Cincinnati; no major pharma partnerships disclosed.

Beyond the preview

Go deeper on Arch Biopartners.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arch Biopartners.